Osman Ozan Yeğit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Osman Ozan Yeğit has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Aslı Gelincik
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye
7 shared publications - Nida Öztop
Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital
6 shared publications - Semra Demir
Division of Immunology and Allergy Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Türkiye
6 shared publications - Derya Unal
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul, Turkey
4 shared publications - Bircan Erden
Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye
3 shared publications - Müge Olgaç
Division of Allergy and Clinical Immunology Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70216
NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria
Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
- 21 October 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70216
Open AccessNSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria
Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
- Open Access
- 15 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7964
Changes in Psychological Burden and Quality of Life During In Vivo Diagnostic Evaluation for Immediate Drug Hypersensitivity: A Prospective Stepwise Study
Background/Objective: The psychological impact of in vivo diagnostic procedures remains poorly understood. We assessed changes in psychological distress and drug hypersensitivity-related quality of life (QoL) throughout a diagnostic evaluation for suspected immediate drug hypersensitivity reactions (IDHRs) and aimed to identify predictors of persistent psychological burden. Methods: This single-center prospective observational longitudinal study included 100 consecutive adults undergoing evaluation for suspected IDHRs. Psychological distress and QoL were assessed using the Depression Anxiety Stress Scale-21 (DASS-21) and the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q). Assessments were performed before and after each diagnostic phase, including skin tests (STs), placebo, and drug provocation tests (DPTs). Results: The mean age was 44.2 ± 12.5 years, and women comprised 72% of the cohort. Depression, anxiety, stress, and DrHy-Q scores significantly decreased after ST, placebo, and DPT compared with baseline measurements. Across diagnostic stages, depression, anxiety, stress, and DrHy-Q scores were significantly lower during the DPT phase than during the ST and placebo phase in both pre-test and post-test measurements (p < 0.01 for pairwise comparisons). The number of prior HSRs showed a weak but significant positive correlation with DrHy-Q scores. In multivariable linear regression analysis, the number of prior HSRs was the only independent predictor of post-DPT DrHy-Q scores (β = 3.43, 95% CI 1.36–5.50, p = 0.001). Patients who avoided the provoked drug despite a negative DPT had higher DPT-post depression, anxiety, stress, and DrHy-Q scores. Conclusions: Psychological burden progressively decreased over the course of the stepwise diagnostic evaluation for suspected IDHRs, although patients with repeated reactions may benefit from additional support.
- 15 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7964
Open AccessChanges in Psychological Burden and Quality of Life During In Vivo Diagnostic Evaluation for Immediate Drug Hypersensitivity: A Prospective Stepwise Study
Background/Objective: The psychological impact of in vivo diagnostic procedures remains poorly understood. We assessed changes in psychological distress and drug hypersensitivity-related quality of life (QoL) throughout a diagnostic evaluation for suspected immediate drug hypersensitivity reactions (IDHRs) and aimed to identify predictors of persistent psychological burden. Methods: This single-center prospective observational longitudinal study included 100 consecutive adults undergoing evaluation for suspected IDHRs. Psychological distress and QoL were assessed using the Depression Anxiety Stress Scale-21 (DASS-21) and the Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q). Assessments were performed before and after each diagnostic phase, including skin tests (STs), placebo, and drug provocation tests (DPTs). Results: The mean age was 44.2 ± 12.5 years, and women comprised 72% of the cohort. Depression, anxiety, stress, and DrHy-Q scores significantly decreased after ST, placebo, and DPT compared with baseline measurements. Across diagnostic stages, depression, anxiety, stress, and DrHy-Q scores were significantly lower during the DPT phase than during the ST and placebo phase in both pre-test and post-test measurements (p < 0.01 for pairwise comparisons). The number of prior HSRs showed a weak but significant positive correlation with DrHy-Q scores. In multivariable linear regression analysis, the number of prior HSRs was the only independent predictor of post-DPT DrHy-Q scores (β = 3.43, 95% CI 1.36–5.50, p = 0.001). Patients who avoided the provoked drug despite a negative DPT had higher DPT-post depression, anxiety, stress, and DrHy-Q scores. Conclusions: Psychological burden progressively decreased over the course of the stepwise diagnostic evaluation for suspected IDHRs, although patients with repeated reactions may benefit from additional support.
- Open Access
- 6 October 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (21)
CHAPLE ‐Like Enteropathy and Renal Microangiopathy in an Adult Patient With CD46 Deficiency
Background: Protein‐losing enteropathy is a rarely reported feature of CD46‐associated disease and may resemble CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein‐losing enteropathy (CHAPLE) syndrome. Associated hypogammaglobulinemia may be mistaken for primary antibody deficiency. Methods: We describe a 23‐year‐old woman with childhood‐onset enteropathy and hypogammaglobulinemia who had received immunoglobulin replacement for presumed common variable immunodeficiency since age 5. Multidisciplinary reassessment incorporated intestinal and renal histopathology, whole‐exome sequencing, family segregation, and longitudinal evaluation of the response to eculizumab. Results: Duodenal biopsy demonstrated intestinal lymphangiectasia, whereas kidney biopsy revealed chronic thrombotic microangiopathy with concurrent PLA2R‐negative membranous nephropathy. Serum C3 and C4 were within reference ranges. Sequencing identified homozygous CD46 c.565T>G (p.Tyr189Asp), with no pathogenic CD55 variant. The diagnostic laboratory reported the CD46 finding as a variant of uncertain significance. Family segregation and published functional evidence supported its clinical relevance, although patient‐specific functional confirmation was unavailable. Eculizumab promptly improved abdominal pain, vomiting, and oral intake. By April 2026, following dose escalation, serum albumin reached 4.3 g/dL and IgG 554 mg/dL, whereas proteinuria decreased from 5.95 to 2.4 g/day. Conclusion: This case supports considering CD46‐associated disease in adults with a CHAPLE‐like phenotype, particularly when enteric protein loss and hypogammaglobulinemia coexist with renal microangiopathy despite normal C3 and C4. The response to complement blockade supports a complement‐mediated disease process. Documented protein loss should prompt reassessment of a presumptive diagnosis of primary antibody deficiency.
- 6 October 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (21)
Open AccessCHAPLE ‐Like Enteropathy and Renal Microangiopathy in an Adult Patient With CD46 Deficiency
Background: Protein‐losing enteropathy is a rarely reported feature of CD46‐associated disease and may resemble CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein‐losing enteropathy (CHAPLE) syndrome. Associated hypogammaglobulinemia may be mistaken for primary antibody deficiency. Methods: We describe a 23‐year‐old woman with childhood‐onset enteropathy and hypogammaglobulinemia who had received immunoglobulin replacement for presumed common variable immunodeficiency since age 5. Multidisciplinary reassessment incorporated intestinal and renal histopathology, whole‐exome sequencing, family segregation, and longitudinal evaluation of the response to eculizumab. Results: Duodenal biopsy demonstrated intestinal lymphangiectasia, whereas kidney biopsy revealed chronic thrombotic microangiopathy with concurrent PLA2R‐negative membranous nephropathy. Serum C3 and C4 were within reference ranges. Sequencing identified homozygous CD46 c.565T>G (p.Tyr189Asp), with no pathogenic CD55 variant. The diagnostic laboratory reported the CD46 finding as a variant of uncertain significance. Family segregation and published functional evidence supported its clinical relevance, although patient‐specific functional confirmation was unavailable. Eculizumab promptly improved abdominal pain, vomiting, and oral intake. By April 2026, following dose escalation, serum albumin reached 4.3 g/dL and IgG 554 mg/dL, whereas proteinuria decreased from 5.95 to 2.4 g/day. Conclusion: This case supports considering CD46‐associated disease in adults with a CHAPLE‐like phenotype, particularly when enteric protein loss and hypogammaglobulinemia coexist with renal microangiopathy despite normal C3 and C4. The response to complement blockade supports a complement‐mediated disease process. Documented protein loss should prompt reassessment of a presumptive diagnosis of primary antibody deficiency.
- Open Access
Hypersensitivity to Excipients in Drugs: An EAACI Position Paper
Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved. Excipient‐related DHR are easily overlooked and may lead to repeated anaphylaxis in patients exposed to pharmaceutical formulations containing different active ingredients. We performed an extensive review of the literature to provide practical recommendations on when to suspect and how to diagnose and manage excipient hypersensitivity. Where literature was limited, the collective experience of the authors was taken into consideration. Excipient hypersensitivity should be suspected in patients with a history of anaphylaxis to multiple drugs with chemically unrelated active ingredients and specific drug classes such as oral laxatives and injectable depot steroids or progestogens. Polyethylene glycol, methylcelluloses, gelatine, povidone and mannitol were identified as the most common culprits of DHR. DHR evaluation should include review of the product monograph to ascertain the presence of possible culprit excipients. Specific diagnostic tests for excipients should be performed when appropriate, including skin, in vitro and provocation testing with pure excipients and drugs with and without the excipient as controls. We provide consensus‐based excipient‐specific recommendations on diagnostic testing based on best available evidence.
Open AccessHypersensitivity to Excipients in Drugs: An EAACI Position Paper
Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved. Excipient‐related DHR are easily overlooked and may lead to repeated anaphylaxis in patients exposed to pharmaceutical formulations containing different active ingredients. We performed an extensive review of the literature to provide practical recommendations on when to suspect and how to diagnose and manage excipient hypersensitivity. Where literature was limited, the collective experience of the authors was taken into consideration. Excipient hypersensitivity should be suspected in patients with a history of anaphylaxis to multiple drugs with chemically unrelated active ingredients and specific drug classes such as oral laxatives and injectable depot steroids or progestogens. Polyethylene glycol, methylcelluloses, gelatine, povidone and mannitol were identified as the most common culprits of DHR. DHR evaluation should include review of the product monograph to ascertain the presence of possible culprit excipients. Specific diagnostic tests for excipients should be performed when appropriate, including skin, in vitro and provocation testing with pure excipients and drugs with and without the excipient as controls. We provide consensus‐based excipient‐specific recommendations on diagnostic testing based on best available evidence.
- 8 July 2024
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (12) , 1663-1671
Long-term use of omalizumab in patients with allergic bronchopulmonary aspergillosis: a tertiary-level care center experience
IntroductionAllergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of Aspergillus fumigatus.ObjectiveThe aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.MethodsIn this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.ResultsEvaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.ConclusionLong-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.
- 8 July 2024
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (12) , 1663-1671
Long-term use of omalizumab in patients with allergic bronchopulmonary aspergillosis: a tertiary-level care center experience
IntroductionAllergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of Aspergillus fumigatus.ObjectiveThe aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.MethodsIn this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.ResultsEvaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.ConclusionLong-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.
- 27 September 2023
- Published by Galenos Yayinevi in Medical Bulletin of Haseki
- Vol. 61 (4) , 267-272
Impact of Direct and Indirect Cat Allergen Exposure Patterns on Allergic Rhinitis and Asthma in Cat-Sensitized Patients
- 27 September 2023
- Published by Galenos Yayinevi in Medical Bulletin of Haseki
- Vol. 61 (4) , 267-272
Impact of Direct and Indirect Cat Allergen Exposure Patterns on Allergic Rhinitis and Asthma in Cat-Sensitized Patients
- Open Access
- 26 August 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (8) , 100810
Comparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?
- 26 August 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (8) , 100810
Open AccessComparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?
- 21 April 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (10) , 1862-1868
Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.
- 21 April 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (10) , 1862-1868
Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.
- Open Access
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 189-197
Impacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 189-197
Open AccessImpacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe
- Open Access
- 13 January 2023
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 19 (1) , 1-5
The first successful desensitization protocol in exenatide allergy: a case report
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported. One report revealed that a patient with a level 1 anaphylaxis according to Brighton Criteria due to an exendin based GLP-1 receptor agonist was able to tolerate liraglutide (Human GLP-1 analogue), the alternative GLP-1 receptor agonist. Since exenatide is the only available GLP-1 receptor agonist covered by insurance in Turkey, a drug desensitization protocol, the only therapeutic method in hypersensitivity reactions used in case of absence of an alternative drug, was considered. Here, we report a successful desensitization protocol for the first time in two obese diabetic patients with an immediate hypersensitivity to exenatide. Case presentation: The first patient was a 47 year-old female. She was referred to our outpatient allergy clinic because of a generalized urticaria developed within minutes after the last dose, following a week of an exenatide BID 5 mcg/20 mcl treatment. Although the reaction was sudden onset, it did not meet the Brighton Criteria of anaphylaxis. The second patient was a 46 year-old female. She had a large local immediate injection site reaction that appeared 15 min following an exenatide BID 5 mcg/20 mcl injection. The injection site reaction was not accompanied by a systemic allergic reaction. We performed desensitization with exenatide to two patients who need GLP-1 receptor agonist treatment. Protocol was completed in 7 steps in approximately 3 h, with the aim of reaching the daily dosage of exenatide. Throughout this process, we observed that both cases tolerated the protocol without any complaints or complications. Following the protocol, the patients safely tolerated the treatment for 3 months. Conclusions: We present the first successful desensitization protocol to exenatide in both local and/or systemic immediate hypersensitivity reactions and indicate the importance of desensitization in patients who do not have alternative therapies.
- 13 January 2023
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 19 (1) , 1-5
Open AccessThe first successful desensitization protocol in exenatide allergy: a case report
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported. One report revealed that a patient with a level 1 anaphylaxis according to Brighton Criteria due to an exendin based GLP-1 receptor agonist was able to tolerate liraglutide (Human GLP-1 analogue), the alternative GLP-1 receptor agonist. Since exenatide is the only available GLP-1 receptor agonist covered by insurance in Turkey, a drug desensitization protocol, the only therapeutic method in hypersensitivity reactions used in case of absence of an alternative drug, was considered. Here, we report a successful desensitization protocol for the first time in two obese diabetic patients with an immediate hypersensitivity to exenatide. Case presentation: The first patient was a 47 year-old female. She was referred to our outpatient allergy clinic because of a generalized urticaria developed within minutes after the last dose, following a week of an exenatide BID 5 mcg/20 mcl treatment. Although the reaction was sudden onset, it did not meet the Brighton Criteria of anaphylaxis. The second patient was a 46 year-old female. She had a large local immediate injection site reaction that appeared 15 min following an exenatide BID 5 mcg/20 mcl injection. The injection site reaction was not accompanied by a systemic allergic reaction. We performed desensitization with exenatide to two patients who need GLP-1 receptor agonist treatment. Protocol was completed in 7 steps in approximately 3 h, with the aim of reaching the daily dosage of exenatide. Throughout this process, we observed that both cases tolerated the protocol without any complaints or complications. Following the protocol, the patients safely tolerated the treatment for 3 months. Conclusions: We present the first successful desensitization protocol to exenatide in both local and/or systemic immediate hypersensitivity reactions and indicate the importance of desensitization in patients who do not have alternative therapies.